Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis

  • Stephanie von Kutzleben, Gareth Pryce, Gavin Giovannoni, David Baker
  • Immunology, January 2017, Wiley
  • DOI: 10.1111/imm.12696

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1111/imm.12696

In partnership with: